Chijioke Nwabueze Iheagwam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chijioke Nwabueze Iheagwam has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Chukwunonso Francis Obi
Department of Veterinary Parasitology and Entomology, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Nigeria
4 shared publications - Ikenna Onyema Ezeh
Department of Veterinary Parasitology and Entomology, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Nigeria
4 shared publications - Michael Ikenna Okpala
Department of Veterinary Parasitology and Entomology, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Nigeria
4 shared publications - Denchris Nnabuike Onah
Department of Veterinary Parasitology and Entomology, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Nigeria
3 shared publications - Ganiyu E. Aneru
Department of Veterinary Parasitology and Entomology, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Enugu State, Nigeria
3 shared publications - Romanus Chukwuduruo Ezeokonkwo
Department of Veterinary Parasitology and Entomology, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Enugu State, Nigeria
3 shared publications
Latest Publications
- 6 June 2026
- Published by Springer Nature in Acta Parasitologica
- Vol. 71 (4)
Differential Virulence and Pathogenicity of Canine Drug-Resistant Trypanosoma brucei brucei Field Isolates in Experimental Murine Infection
African animal trypanosomosis remains a significant veterinary and economic threat in sub-Saharan Africa, worsened by rising multidrug resistance. In dogs, Trypanosoma brucei brucei infections are often acute and fatal, yet the relationship between drug resistance and pathogenicity remains poorly defined. This study aimed to compare the virulence and pathogenicity of three canine multidrug-resistant T. b. brucei field isolates from Southeast Nigeria using an experimental murine model. Twenty Sprague Dawley rats were randomly assigned to four groups (n = 5). Groups I-III received intraperitoneal inoculations of isolates from a veterinary hospital (VTH), Orie Orba dog market (Orba), and Nkwo Ibagwa dog market (Iba), respectively, while Group IV served as uninfected controls. Clinical progression, parasitaemia dynamics, haematological indices, and survival times were monitored. The isolates displayed strikingly heterogeneous pathogenic profiles. The Orba isolate was the most virulent, with the shortest pre-patent period (3-5 days), rapid parasitaemia onset, profound anaemia, and the lowest mean survival (14.8 ± 1.7 days). The VTH isolate showed attenuated virulence and extended survival (27.8 ± 2.5 days), whereas the Iba isolate exhibited intermediate characteristics (survival time: 22.6 ± 2.3 days). All infected rats developed progressive anaemia and leucocytosis, though severity varied by isolate. Multidrug resistance does not inevitably reduce T. b. brucei virulence. The MDR Orba isolate drove the most aggressive disease, indicating that resistant parasites can remain highly pathogenic. Our findings suggest that local selection pressures (drug exposure, host immunity) shape virulence traits. These results support the need for region-specific control strategies for animal trypanosomosis.
- 6 June 2026
- Published by Springer Nature in Acta Parasitologica
- Vol. 71 (4)
Differential Virulence and Pathogenicity of Canine Drug-Resistant Trypanosoma brucei brucei Field Isolates in Experimental Murine Infection
African animal trypanosomosis remains a significant veterinary and economic threat in sub-Saharan Africa, worsened by rising multidrug resistance. In dogs, Trypanosoma brucei brucei infections are often acute and fatal, yet the relationship between drug resistance and pathogenicity remains poorly defined. This study aimed to compare the virulence and pathogenicity of three canine multidrug-resistant T. b. brucei field isolates from Southeast Nigeria using an experimental murine model. Twenty Sprague Dawley rats were randomly assigned to four groups (n = 5). Groups I-III received intraperitoneal inoculations of isolates from a veterinary hospital (VTH), Orie Orba dog market (Orba), and Nkwo Ibagwa dog market (Iba), respectively, while Group IV served as uninfected controls. Clinical progression, parasitaemia dynamics, haematological indices, and survival times were monitored. The isolates displayed strikingly heterogeneous pathogenic profiles. The Orba isolate was the most virulent, with the shortest pre-patent period (3-5 days), rapid parasitaemia onset, profound anaemia, and the lowest mean survival (14.8 ± 1.7 days). The VTH isolate showed attenuated virulence and extended survival (27.8 ± 2.5 days), whereas the Iba isolate exhibited intermediate characteristics (survival time: 22.6 ± 2.3 days). All infected rats developed progressive anaemia and leucocytosis, though severity varied by isolate. Multidrug resistance does not inevitably reduce T. b. brucei virulence. The MDR Orba isolate drove the most aggressive disease, indicating that resistant parasites can remain highly pathogenic. Our findings suggest that local selection pressures (drug exposure, host immunity) shape virulence traits. These results support the need for region-specific control strategies for animal trypanosomosis.
- 24 October 2025
- Published by Springer Nature in Journal of Parasitic Diseases
- Vol. 49 (4) , 1086-1099
Comparative efficacy of trypanocide brands against experimental Trypanosoma brucei brucei infections in mice
African animal trypanosomosis is a major constraint to livestock production in sub-Saharan Africa. Chemotherapy remains the primary control strategy, but the efficacy of various trypanocide brands in circulation in Africa, especially in Nigeria, remains uncertain. This study aimed to evaluate and compare the efficacy of selected, commonly used commercial brands of diminazene aceturate and isometamidium chloride against experimental Trypanosoma brucei brucei infection in mice. A total of 35 adult male mice were randomly assigned to seven groups of five mice each. Group 1 served as the uninfected control, while groups 2–7 were intraperitoneally (i.p.) infected with 10⁶ trypanosomes. Group 2 was left untreated, while groups 3–5 were treated with diminazene aceturate brands (TrypanocideDA 1-3) respectively at a dose of 7.0 mg/kg on day 13 post-infection (p.i). Groups 6 and 7 received isometamidium chloride brands (TrypanocideISM 1 and 2) respectively at a dose of 0.5 mg/kg on day 13 p.i. Efficacy was assessed through clinical signs, parasitaemia, haematological parameters (PCV, Hb concentration, erythrocyte count, leucocyte counts), parasite clearance time, body weight, rectal temperature, and survival. Parasite clearance was fastest in group 3 (2.4 days post-treatment) compared to other treated groups (3 days post-treatment). Diminazene aceturate-treated groups exhibited shorter relapse times than isometamidium chloride-treated groups. Treatment reversed the reduction in haematological indices across all groups. The study concluded that isometamidium chloride brands demonstrated superior efficacy compared to diminazene aceturate brands in treating T. brucei brucei infections.
- 24 October 2025
- Published by Springer Nature in Journal of Parasitic Diseases
- Vol. 49 (4) , 1086-1099
Comparative efficacy of trypanocide brands against experimental Trypanosoma brucei brucei infections in mice
African animal trypanosomosis is a major constraint to livestock production in sub-Saharan Africa. Chemotherapy remains the primary control strategy, but the efficacy of various trypanocide brands in circulation in Africa, especially in Nigeria, remains uncertain. This study aimed to evaluate and compare the efficacy of selected, commonly used commercial brands of diminazene aceturate and isometamidium chloride against experimental Trypanosoma brucei brucei infection in mice. A total of 35 adult male mice were randomly assigned to seven groups of five mice each. Group 1 served as the uninfected control, while groups 2–7 were intraperitoneally (i.p.) infected with 10⁶ trypanosomes. Group 2 was left untreated, while groups 3–5 were treated with diminazene aceturate brands (TrypanocideDA 1-3) respectively at a dose of 7.0 mg/kg on day 13 post-infection (p.i). Groups 6 and 7 received isometamidium chloride brands (TrypanocideISM 1 and 2) respectively at a dose of 0.5 mg/kg on day 13 p.i. Efficacy was assessed through clinical signs, parasitaemia, haematological parameters (PCV, Hb concentration, erythrocyte count, leucocyte counts), parasite clearance time, body weight, rectal temperature, and survival. Parasite clearance was fastest in group 3 (2.4 days post-treatment) compared to other treated groups (3 days post-treatment). Diminazene aceturate-treated groups exhibited shorter relapse times than isometamidium chloride-treated groups. Treatment reversed the reduction in haematological indices across all groups. The study concluded that isometamidium chloride brands demonstrated superior efficacy compared to diminazene aceturate brands in treating T. brucei brucei infections.